PHESGO

Phase 3Small molecule

Roche

PHESGO is one of 93 small molecule programs targeting Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Metastatic Breast CancerRecruiting

Locally Advanced or Metastatic Breast CancerActive, not recruiting

Breast Cancer FemaleRecruiting

Breast CancerPhase 2

Active, not recruiting

Metastatic Breast CancerPhase 3

Recruiting

Locally Advanced or Metastatic Breast CancerPhase 3

Active, not recruiting

Breast Cancer FemalePhase 2

Recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

PHESGO

Roche

Phase 3

1 2

Adenocard

Astellas

Preclinical

2 3

Blenoxane

Bristol-Myers Squibb

Preclinical

1 4

Lexiscan

Astellas

Preclinical

1 5

Voltaren

Novartis

Preclinical

1 6

Zolymbus

AbbVie

Preclinical

1 7

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 8

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 9

Duragesic-100

CCephalon

Preclinical

2 10

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

HER2-Positive Breast Cancer

NCT05306041

Q4 2030

Phase 3Active, not recruiting

Locally Advanced or Metastatic Breast Cancer

NCT05296798

Q4 2032

Phase 2Active, not recruiting

Breast Cancer

NCT06068985

Phase 3Recruiting

Metastatic Breast Cancer

NCT05894239

Q1 2033

Phase 2Recruiting

Breast Cancer Female

NCT06439693

Clinical

Trials by Indication[1]

HER2-positive Breast Cancer1 trial

A Randomized, Open-label, Phase II Trial Comparing Neoadjuvant Endocrine Therapy in Combination With Trastuzumab, Pertuzumab +/- the PI3K Inhibitor Inavolisib in Patients With HER2-positive, HR-positive, PIK3CA Mutant Early Breast Cancer-GeparPiPPa

Recruiting·GGBG Forschungs GmbH·Phase 2·NCT05306041·170 enrolled

Breast Cancer1 trial

Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade

Active, not recruiting·LLatin American Cooperative Oncology Group·Phase 2·NCT06068985·63 enrolled

Metastatic Breast Cancer1 trial

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Recruiting· Roche logo

Roche·Phase 3·NCT05894239·230 enrolled

Breast Cancer Female1 trial

A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer: The SAPPHO Study

Recruiting·DDana-Farber Cancer Institute·Phase 2·NCT06439693·72 enrolled

Locally Advanced or Metastatic Breast Cancer1 trial

A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Giredestrant in Combination With Phesgo Versus Phesgo After Induction Therapy With Phesgo + Taxane in Patients With Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally-Advanced or Metastatic Breast Cancer

Active, not recruiting· Roche logo

Roche·Phase 3·NCT05296798·922 enrolled

Regulatory

FDA Approval Timeline[4]

Jun 29, 2020

PHESGO

BLA BLA761170

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for PHESGO. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PHESGO compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PHESGO. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA761170). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Roche

PHESGO

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2030

Q4 2032

Q1 2033

Trials by Indication[1]

HER2-positive Breast Cancer1 trial

Breast Cancer1 trial

Metastatic Breast Cancer1 trial

Breast Cancer Female1 trial

Locally Advanced or Metastatic Breast Cancer1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News